FDA delays review of AZ's Brilinta

AstraZeneca said today that the FDA has extended the time to complete its review of its application for Brilinta (ticagrelor). The PDUFA date has been moved from September 16 to December 16. Release

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships, but then dropped the projects after Voyager completed research activities.